Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by NEOS Investment Management LLC

NEOS Investment Management LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,323 shares of the biopharmaceutical company’s stock after selling 1,853 shares during the quarter. NEOS Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $3,841,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Regeneron Pharmaceuticals Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $1,045,822,000. Raymond James Financial Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $65,295,000. Jennison Associates LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $61,160,000. Proficio Capital Partners LLC increased its stake in Alnylam Pharmaceuticals by 25,929.6% in the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock worth $45,570,000 after purchasing an additional 192,916 shares in the last quarter. Finally, Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $41,529,000. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ALNY. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $280.00 to $328.00 in a research report on Monday. Finally, Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $312.30.

Alnylam Pharmaceuticals Stock Up 0.7 %

Shares of ALNY stock opened at $271.02 on Friday. The stock’s 50 day simple moving average is $259.42 and its 200 day simple moving average is $260.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market capitalization of $35.09 billion, a price-to-earnings ratio of -124.89 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last ninety days. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.